Achaogen Announces Multiple Plazomicin Presentations at ASM Microbe 2017 Annual Meeting
26 mai 2017 08h01 HE
|
Achaogen Inc.
- Two oral presentations highlighting data from plazomicin Phase 3 EPIC and CARE clinical trials - - Eleven poster presentations highlighting plazomicin’s activity against MDR Enterobacteriaceae,...
Achaogen Announces Pricing of Public Offering of Common Stock
25 mai 2017 08h00 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., May 25, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...
Plazomicin Granted FDA Breakthrough Therapy Designation
23 mai 2017 16h07 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug...
Achaogen Announces Proposed Public Offering of Common Stock
23 mai 2017 16h02 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...
Achaogen Reports First Quarter 2017 Financial Results and Provides Corporate Update
08 mai 2017 16h01 HE
|
Achaogen Inc.
-- Presented additional Phase 3 EPIC and CARE trial data highlighting the safety and efficacy of plazomicin during late-breaker session at ECCMID -- -- Plazomicin registration activities on track;...
Achaogen Receives Investment from the Bill & Melinda Gates Foundation to Develop Antibodies Against Gram-Negative Bacteria
05 mai 2017 08h01 HE
|
Achaogen Inc.
The Bill & Melinda Gates Foundation is committing up to $20 million in grant funding and equity investment to further the development of an antibody platform and discovery of monoclonal antibody...
Achaogen to Host Conference Call and Webcast of First Quarter 2017 Financial Results on May 8, 2017
01 mai 2017 08h01 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., May 01, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company discovering and developing innovative antibacterials addressing...
Achaogen Unveils Data Highlighting the Effectiveness of Plazomicin Against MDR Gram-Negative Bacteria at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
24 avr. 2017 03h01 HE
|
Achaogen Inc.
-- Evaluation of EPIC Phase 3 data demonstrates sustained clinical cure with plazomicin compared to higher clinical relapse rate with meropenem -- -- 28-Day mortality benefit of plazomicin versus...
Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
13 avr. 2017 08h01 HE
|
Achaogen Inc.
-- Late-breaking oral presentations to highlight data from plazomicin Phase 3 EPIC and CARE clinical trials -- -- Newly-released in vitro data demonstrates activity of plazomicin against a large...
Achaogen to Present at Needham & Company’s 16th Annual Healthcare Conference
30 mars 2017 08h01 HE
|
Achaogen Inc.
SOUTH SAN FRANCISCO, Calif., March 30, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing novel antibacterials addressing multi-drug resistant...